NewAmsterdam Pharma (NASDAQ:NAMS) Shares Acquired by Barclays PLC

Barclays PLC lifted its stake in shares of NewAmsterdam Pharma (NASDAQ:NAMS) by 1,813.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,596 shares of the company’s stock after acquiring an additional 7,199 shares during the quarter. Barclays PLC’s holdings in NewAmsterdam Pharma were worth $126,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Quarry LP boosted its stake in shares of NewAmsterdam Pharma by 2,469.2% in the 3rd quarter. Quarry LP now owns 6,500 shares of the company’s stock valued at $108,000 after buying an additional 6,247 shares during the period. Bellevue Group AG acquired a new stake in shares of NewAmsterdam Pharma during the third quarter worth about $128,000. XTX Topco Ltd acquired a new stake in shares of NewAmsterdam Pharma in the 3rd quarter valued at about $187,000. M&T Bank Corp grew its position in NewAmsterdam Pharma by 54.1% during the 3rd quarter. M&T Bank Corp now owns 27,328 shares of the company’s stock worth $454,000 after purchasing an additional 9,593 shares during the last quarter. Finally, Sei Investments Co. lifted its holdings in shares of NewAmsterdam Pharma by 49.1% during the second quarter. Sei Investments Co. now owns 24,561 shares of the company’s stock worth $472,000 after purchasing an additional 8,087 shares during the period. 89.89% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. HC Wainwright restated a “buy” rating and issued a $48.00 target price on shares of NewAmsterdam Pharma in a research note on Tuesday, January 14th. Needham & Company LLC reiterated a “buy” rating and set a $36.00 target price on shares of NewAmsterdam Pharma in a research report on Thursday, December 5th. Finally, Scotiabank raised their price target on NewAmsterdam Pharma from $35.00 to $47.00 and gave the company a “sector outperform” rating in a report on Wednesday, December 11th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $39.80.

Insider Buying and Selling

In related news, major shareholder Nap B.V. Forgrowth sold 33,273 shares of the business’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $25.08, for a total value of $834,486.84. Following the completion of the transaction, the insider now owns 11,778,760 shares of the company’s stock, valued at approximately $295,411,300.80. The trade was a 0.28 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold 446,730 shares of company stock worth $11,438,695 in the last ninety days. Insiders own 19.50% of the company’s stock.

NewAmsterdam Pharma Stock Down 0.7 %

NASDAQ:NAMS opened at $23.20 on Friday. The stock has a fifty day simple moving average of $23.58 and a 200-day simple moving average of $19.91. NewAmsterdam Pharma has a 52-week low of $15.19 and a 52-week high of $27.29.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.